Patents Represented by Attorney, Agent or Law Firm Cheryl L. Becker
  • Patent number: 6083934
    Abstract: A nutritional formulation containing an effective amount of Lacto-N-neoTetraose to simulate the growth and/or metabolic activity of Bifidobacterium is provided. A process of inhibiting bacterial infections caused by Bacteroides, Clostridium, and E. coli including the step of feeding the nutritional composition to a subject is also provided.
    Type: Grant
    Filed: March 19, 1999
    Date of Patent: July 4, 2000
    Assignee: Abbott Laboratories
    Inventors: Pedro A. Prieto, Terry A. Kroening
  • Patent number: 6071718
    Abstract: The subject invention relates to methods of processing and producing recombinant proteins in vivo, for example, recombinant phosphorylated beta-casein. The subject invention also relates to the proteins produced by these methods as well as to uses of these proteins.
    Type: Grant
    Filed: November 27, 1996
    Date of Patent: June 6, 2000
    Assignee: Abbott Laboratories
    Inventors: Pradip Mukerji, Robert George Hards, Jennifer Marie Thurmond, Amanda Eun-Yeong Leonard
  • Patent number: 6051374
    Abstract: Hepatitis GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV nucleic acid or amino acid sequences.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 18, 2000
    Assignee: Abbott Laboratories
    Inventors: John N. Simons, Tami J. Pilot-Matias, George J. Dawson, George G. Schlauder, Suresh M. Desai, Thomas P. Leary, Anthony Scott Muerhoff, James Carl Erker, Sheri L. Buijk, Isa K. Mushahwar
  • Patent number: 6045854
    Abstract: A nutritional formulation containing at least one of the following oligosaccharides: from about 400 to about 3500 mg/L of 3-fucosyllactose; from about 200 to about 2200 mg/L of lacto-N-fucopentaose III; from about 100 to about 1500 mg/L of lacto-N-fucopentaose II; from about 100 to about 2500 mg/L of difucosyllactose; from about 500 to about 4500 mg/L of 2' fucosyllactose; from about 250 to about 3300 mg/L of lacto-N-fucopentaose I; from about 100 to about 900 mg/L of Lacto-N-neoTetraose; from about 50 to about 2300 mg/L of lacto-N-fucopentaose V; or from about 300 to about 2800 mg/L of lacto-N-tetraose.
    Type: Grant
    Filed: March 31, 1997
    Date of Patent: April 4, 2000
    Assignee: Abbott Laboraties
    Inventors: Pedro A. Prieto, Stephen J. Kirchner, Renee M. Erney
  • Patent number: 6020122
    Abstract: This invention provides a novel mammalian expression system that is capable of generating high levels of expressed hepatitis C virus (HCV) proteins which have previously proved difficult to express due to their non-secretory properties. In particular, the invention provides a plasmid for the expression of the HCV second envelope protein (E2) designated p577. This plasmid encodes a recombinant protein comprising the immunoglobulin signal peptide and amino acids 388-664 of the HCV E2 glycoprotein. This unique expression system produces high levels of HCV proteins that are properly processed, glycosylated, and folded.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 1, 2000
    Assignee: Abbott Laboratories
    Inventors: Gregory F. Okasinski, Verlyn G. Schaefer, Thomas S. Suhar, Richard R. Lesniewski
  • Patent number: 6015662
    Abstract: The present invention relates to the use of a reagent that binds specifically to a predetermined ligand, contains one or more antibody constant region epitopes, and is uniform in specificity and affinity. The reagent can be produced continually, in the manufacture of calibrators (standards) and/or controls for diagnostic kits designed to qualitatively or quantitatively measure antibodies specific for a desired ligand. For example, the present invention encompasses recombinant mouse-human chimeric antibodies which may be used as calibrators (standards) and/or positive controls in assays and kits which measure human antibodies. Any species may be used in creating the chimeric antibodies, and the presence of any corresponding species of antibody may be detected.
    Type: Grant
    Filed: January 23, 1996
    Date of Patent: January 18, 2000
    Assignee: Abbott Laboratories
    Inventors: John R. Hackett, Jr., Jane A. Hoff, David H. Ostrow, Alan M. Golden
  • Patent number: 5981172
    Abstract: Hepatitus GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and theraeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV nucleic acid or amino acid sequences.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: November 9, 1999
    Assignee: Abbott Laboratories
    Inventors: John N. Simons, Tami J. Pilot-Matias, George J. Dawson, George G. Schlauder, Suresh M. Desai, Thomas P. Leary, Anthony Scott Muerhoff, Sheri L. Buijk, James Carl Erker, Isa K. Mushahwar
  • Patent number: 5965702
    Abstract: This invention relates generally to an assay for Lyme disease which detects the antibody to Borrelia burgdorferi, the causative agent of Lyme disease. More specifically, the assay employs antigens derived from amino acid regions in the flagellum of Borrelia burgdorferi. These antigens are immunoreactive with antibodies to Borrelia burgdorferi but are not substantially immunoreactive with antibodies to Treponema pallidum, the syphilis causing agent. DNA sequences of the antigens, clones and vectors containing the DNA sequences are also disclosed. Polypeptides derived therefrom can be used as reagents for the detection of antibody to Borrelia burgdorferi in the body fluids from individuals with Lyme disease.
    Type: Grant
    Filed: October 21, 1991
    Date of Patent: October 12, 1999
    Assignee: Abbott Laboratories
    Inventors: John M. Robinson, Tami J. Pilot-Matias, Jeffrey C. Hunt
  • Patent number: 5945314
    Abstract: The present invention relates to a process for synthesizing oligosaccharides. The process involves contacting an acceptor moiety with unpurified sugar-nucleotides and/or unpurified glycosyltransferase to synthesize oligosaccharides.
    Type: Grant
    Filed: March 31, 1997
    Date of Patent: August 31, 1999
    Assignee: Abbott Laboratories
    Inventors: Pedro A. Prieto, Karen M. Kleman-Leyer
  • Patent number: 5942254
    Abstract: The present invention provides a plasmid containing a promoter sequence, a nucleotide sequence encoding an exogenous protein, and a nucleotide sequence encoding an enzyme capable of modifying the exogenous protein. In a specific embodiment of the invention the encoded exogenous protein is human .beta.-casein and the encoded enzyme is a human kinase capable of phosphorylating recombinant .beta.-casein in a bacterial system. Phosphorylated recombinant human .beta.-casein synthesized using the plasmid of the invention is shown to have the same bioactivity as native human .beta.-casein.
    Type: Grant
    Filed: November 6, 1995
    Date of Patent: August 24, 1999
    Assignee: Abbott Laboratories
    Inventors: Pradip Mukerji, Jennifer Marie Thurmond, Lennart Hansson, Jeffrey Harris Baxter, Robert George Hards
  • Patent number: 5939265
    Abstract: A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as LU103 and transcribed from lung tissue is described. A fully sequenced clone representing the longest continuous sequence of LU103 is also disclosed. These sequences are useful for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the lung such as lung cancer.
    Type: Grant
    Filed: November 5, 1997
    Date of Patent: August 17, 1999
    Assignee: Abbott Laboratories
    Inventors: Maurice Cohen, Paula N. Friedman, Julian Gordon, Steven C. Hodges, Michael R. Klass, Jon D. Kratochvil, Lisa Roberts-Rapp, John C. Russell, Steven D. Stroupe
  • Patent number: 5919638
    Abstract: A set of contiguous and partially overlapping oligonucleotide sequences transcribed from a prostate. Also provided are human disease-specific polypeptides translated from said oligonucleotide sequences and a procedure for producing such polypeptide by recombinant techniques. Antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat prostate diseases, tumors or metastastases are disclosed. Also disclosed is the use of said antibodies, agonists and inhibitors as well as the nucleic acid sequences to screen for, diagnose, prognose, stage and monitor conditions and diseases attributable to prostate tumor, especially prostate cancer. The use of said partial sequence to provide antibodies, agonists and inhibitors as well as partial nucleic acid sequences to screen for, diagnose, stage and monitor diseases and associated with prostate tumor.
    Type: Grant
    Filed: October 8, 1996
    Date of Patent: July 6, 1999
    Assignee: Abbott Laboratories
    Inventors: John C. Russell, Maurice Cohen, Paula N. Friedman, Michael R. Klass, Lisa Roberts-Rapp
  • Patent number: 5906982
    Abstract: A nutritional formulation containing an effective amount of Lacto-N-neoTetraose to simulate the growth and/or metabolic activity of Bifidobacterium is provided. A process of inhibiting bacterial infections including the step of feeding the nutritional composition to a subject is also provided.
    Type: Grant
    Filed: March 31, 1997
    Date of Patent: May 25, 1999
    Assignee: Abbott Laboratories
    Inventors: Pedro A. Prieto, Terry A. Kroening
  • Patent number: 5892070
    Abstract: The invention relates to transgenic non-human mammals characterized in that the genome of said mammals contain at least one heterologous gene encoding for the production of heterologous catalytic entity selected from the group consisting of enzymes and antibodies, and wherein said catalytic entity produces a second heterologous product in the milk of said mammal. Especially useful in the practice of the invention are human glycosyltransferases and transgenic sheep, goats and cows. The heterologous product includes oligosaccharides and glycoconjugates. Specifically exemplified, is the production of 2'-fucosyl-lactose in the milk of transgenic mice which contain and express a transgene encoding .alpha.-1,2-fucosyltransferase operatively linked to a mammary gland specific promoter.
    Type: Grant
    Filed: September 10, 1996
    Date of Patent: April 6, 1999
    Assignee: Abbott Laboratories
    Inventors: Pedro Antonio Prieto, David Fletcher Smith, Richard Dale Cummings, John Joseph Kopchick, Pradip Mukerji, Kelley Wilson Moremen, James Michael Pierce
  • Patent number: 5891698
    Abstract: The invention relates to humanized milk. The milk is produced by a non-human transgenic mammal wherein the genome of said transgenic non-human mammal contains at least one heterologous gene encoding for a human catalytic entity and wherein the catalytic entity produces oligosaccharides and glycoconjugates that are present in the milk of said transgenic non-human mammal. An especially useful catalytic entity is human glycosyltransferases which produce oligosaccharides and glyconjugates. Specifically exemplified, is the production of 2'-fucosyl-lactose in the milk of transgenic mice which contain and express a transgene encoding .alpha.-1,2-fucosyltransferase operatively linked to a mammary gland specific promoter. A method of obtaining humanized milk is disclosed.
    Type: Grant
    Filed: May 2, 1995
    Date of Patent: April 6, 1999
    Assignee: Abbott Laboratories
    Inventors: Pedro Antonio Prieto, David Fletcher Smith, Richard Dale Cummings, John Joseph Kopchick, Pradip Mukerji, Kelley Wilson Moremen, James Michael Pierce
  • Patent number: 5854001
    Abstract: Mammalian expression systems for the production of HCV fusion proteins. Such expression systems provide high yields of HCV fusion proteins, and enable the development of diagnostic and therapeutic reagents which contain glycosylated structural antigens and also allow for the isolation of the HCV etiological agent.
    Type: Grant
    Filed: September 18, 1996
    Date of Patent: December 29, 1998
    Assignee: Abbott Laboratories
    Inventors: James M. Casey, Suzanne L. Bode, Billy J. Zeck, Julie Yamaguchi, Donald E. Frail, Suresh M. Desai, Sushil G. Devare
  • Patent number: 5807702
    Abstract: The present invention provides a method of producing phophorylated, recombinant human .beta.-casein having 3 to 5 phosphates in a bacterial cell using a single vector containing in tandem both the nucleotide sequence encoding .beta.-casein and a sequence encoding the enzyme CKII .beta..alpha. which is capable of phosphorylating human .beta.-casein.
    Type: Grant
    Filed: November 6, 1995
    Date of Patent: September 15, 1998
    Assignee: Abbott Laboratories
    Inventors: Pradip Mukerji, Jennifer Marie Thurmond, Lennart Hansson, Jeffrey Harris Baxter, Robert George Hards
  • Patent number: 5753430
    Abstract: Monoclonal antibodies which specifically bind to either Hepatitis C Virus C-100 protein, Hepatitis C Virus 33C protein and Hepatitis C Virus CORE protein, and hybridomas which produce these monoclonal antibodies. Also provided are methods for using these monoclonal antibodies and assay kits containing these antibodies.
    Type: Grant
    Filed: September 29, 1994
    Date of Patent: May 19, 1998
    Assignee: Abbott Laboratories
    Inventors: Smriti U. Mehta, Jill Johnson, Sheela M. George, Suresh M. Desai, Larry T. Mimms, Sushil G. Devare, Joan D. Tyner, Mary S. Gibadlo
  • Patent number: 5750176
    Abstract: The invention relates to the milk of a transgenic non-human mammal. The milk is characterized in that it contains heterologous components produced as the secondary gene products of a heterologous gene contained in the genome of the transgenic non-human mammal. The heterologous gene encodes a heterologous catalytic entity such as a human enzyme selected from the group consisting of glycosyltransferases, phosphorylases, hydroxylases, peptidases and sulfotransferases. Especially useful in the practice of the invention are human glycosyltransferases. The desired heterologous components include oligosaccahrides, glycoconjugates. Specifically exemplified, is the production of 2'-fucosyl-lactose in the milk of transgenic mice which contain and express a transgene encoding .alpha.-1,2-fucosyltransferase operatively linked to a mammary gland specific promoter.
    Type: Grant
    Filed: March 9, 1994
    Date of Patent: May 12, 1998
    Assignee: Abbott Laboratories
    Inventors: Pedro Antonio Prieto, David Fletcher Smith, Richard Dale Cummings, John Joseph Kopchick, Pradip Mukerji, Kelley Wilson Moremen, James Michael Pierce
  • Patent number: 5710044
    Abstract: The present invention provides a plasmid containing a promoter sequence, a nucleotide sequence encoding an exogenous protein, and a nucleotide sequence encoding an enzyme capable of modifying the exogenous protein. In a specific embodiment of the invention the encoded exogenous protein is human .beta.-casein and the encoded enzyme is a human kinase capable of phosphorylating recombinant .beta.-casein in a bacterial system. Phosphorylated recombinant human .beta.-casein having 3 or more phosphate groups and synthesized using the plasmid of the invention is shown to have the same bioactivity as native human .beta.-casein.
    Type: Grant
    Filed: November 6, 1995
    Date of Patent: January 20, 1998
    Assignee: Abbott Laboratories
    Inventors: Pradip Mukerji, Jennifer Marie Thurmond, Lennart Hansson, Jeffrey Harris Baxter, Robert George Hards